Hospital
PRHC Ennis LP
PRHC Ennis LP was paid $1.81M by Medicaid between Jan 2020 and Nov 2024, across 52 billing codes. Its largest line is 99284, emergency room visit (serious) — 45% of everything it billed.
33Billing provider infoPRHC ENNIS LP
ENNIS, TX 75119
ENNIS, TX 75119
33aNPI1700805678assigned 07/19/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$1.81M
24GClaims42,125
24DCodes billed52
24AFirst – last monthJan 2020 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Texas
Rank by total paid#50 of 109
Median peer was paid$1.15M
This provider vs. median1.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official TEAGUE, KATHY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 955 | $38K | |
| 2021 | 11,925 | $515K | |
| 2022 | 14,569 | $692K | |
| 2023 | 11,629 | $437K | |
| 2024incomplete | 3,047 | $126K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 45% | 3,541 | 3,258 | $808K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 27% | 7,291 | 6,995 | $480K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 4.2% | 3,038 | 2,736 | $76K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.8% | 1,265 | 1,248 | $69K |
| 71046 | Radiologic examination, chest; 2 views | 3.1% | 863 | 789 | $57K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.5% | 2,896 | 2,788 | $45K |
| 87430 | 2.2% | 3,186 | 3,083 | $40K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.8% | 3,551 | 3,410 | $32K |
| 87070 | 1.7% | 2,574 | 2,477 | $31K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.4% | 264 | 260 | $25K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.1% | 263 | 247 | $21K |
| 80053 | Comprehensive metabolic panel | <1% | 2,412 | 1,981 | $15K |
40 more codes
| 71045 | Radiologic examination, chest; single view | <1% | 705 | $14K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 405 | $13K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 143 | $12K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 2,639 | $12K |
| 99285 | Emergency room visit (most serious) | <1% | 106 | $8K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 48 | $8K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 264 | $7K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 370 | $6K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 240 | $6K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 639 | $4K |
| 81001 | <1% | 1,232 | $3K | |
| 87807 | <1% | 242 | $3K | |
| 81003 | <1% | 917 | $3K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 47 | $2K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 32 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 229 | $1K |
| 83880 | <1% | 144 | $1K | |
| 84484 | <1% | 376 | $1K | |
| 81025 | <1% | 143 | $807.20 | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 147 | $557.46 |
| 86140 | <1% | 173 | $446.58 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 139 | $292.20 |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 339 | $191.58 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 28 | $156.51 |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 339 | $152.54 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 286 | $141.24 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 12 | $124.07 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 165 | $116.30 |
| 83735 | <1% | 76 | $108.12 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 13 | $82.53 |
| 83690 | <1% | 28 | $68.03 | |
| 0031A | <1% | 29 | $59.98 | |
| 82150 | <1% | 13 | $48.15 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 46 | $39.18 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 40 | $34.00 |
| 87077 | <1% | 14 | $26.14 | |
| 80061 | Lipid panel | <1% | 44 | $21.38 |
| 0012A | <1% | 18 | $5.94 | |
| A9270 | Non-covered item or service | 0% | 98 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTEAGUE, KATHY (VICE PRESIDENT, CORPORATE SECRETARY)
| Provider | Location | Paid |
|---|---|---|
| Rchp-Wilmington, LLC | Wilmington, OH | $13.53M |
| Providence Hospital, LLC | Columbia, SC | $12.68M |
| Vaughan Regional Medical Center LLC | Selma, AL | $8.15M |
| Kershaw Hospital LLC | Camden, SC | $7.93M |
| Bolivar Physician Practices LLC | Cleveland, MS | $3.05M |
| Wilmington Physicians Group LLC | Wilmington, OH | $3.04M |
| Phc-Morgan City LP | Morgan City, LA | $2.37M |
| Community Hospital of Andalusia LLC | Andalusia, AL | $2.27M |
| Vaughan Regional Medical Center LLC | Marion, AL | $2.15M |
| Andalusia Physician Practices LLC | Andalusia, AL | $847K |
| Meadowview Physician Practice LLC | Maysville, KY | $783K |
| Logan Physician Practice LLC | Auburn, KY | $458K |
| Logan Physician Practice LLC | Russellville, KY | $317K |
| Kentucky Mso LLC | Georgetown, KY | $248K |
| Rchp-Wilmington, LLC | Wilmington, OH | $165K |
| Meadowview Physician Practice LLC | Maysville, KY | $140K |
| Amg-Southern Tennessee LLC | Monteagle, TN | $136K |
| Lake Cumberland Physician Practices LLC | Somerset, KY | $135K |
| Lake Cumberland Physician Practices LLC | Somerset, KY | $57K |
| Kershaw Hospital LLC | Lugoff, SC | $49K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.